Antibodies, Viral; Humans; SARS-CoV-2; COVID-19; Hematology; Oncology; Cancer Research
Disciplines :
Immunology & infectious disease
Author, co-author :
Poncelet, Arthur ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) ; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Verschelden, Gil; Clinic of Infectious Disease, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Colard, Martin; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Hildebrand, Marc; Department of Internal Medicine, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Hites, Maya; Clinic of Infectious Disease, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Yin, Nicolas; Department of Microbiology, Laboratoire hospitalier universitaire de Bruxelles (LHUB-ULB)- Université libre de Bruxelles, Brussels, Belgium
Michel, Charlotte; Department of Microbiology, Laboratoire hospitalier universitaire de Bruxelles (LHUB-ULB)- Université libre de Bruxelles, Brussels, Belgium
Grimaldi, David; Departement of Intensive Care, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
De Wilde, Virginie; Departement of Hematology, CUB-Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Language :
English
Title :
Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection.
REGN-COV2 (cocktail of two antibodies, casirivimab and imdevimab) was provided by Regeneron Pharmaceuticals, Inc. for the purpose of emergency compassionate use treatment
Zeidan AM, Boddu PC, Patnaik MM, et al. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020; 7 (8): e601–12–e612.
Girmenia C, Gentile G, Micozzi A, et al. COVID-19 in patients with hematologic disorders undergoing therapy: Perspective of a large referral hematology center in rome. Acta Haematol. 2020; 143 (6): 574–582.
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and Meta-analysis of 3377 patients. Blood. 2020; 136 (25): 2881–2892.;
Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020; 190 (5): e279–e282.
Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with Cancer. Cell. 2020; 183 (7): 1901–1912.e9.
Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020 222(7):1103–1107. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454684/
Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020; 383 (26): 2586–2588. Dec 1null.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - Final report. N Engl J Med. 2020; 383 (19): 1813–1826.
Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020; 136 (20): 2290–2295.
Weinreich DM, Sivapalasingam S, Norton T, et al.; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021; 384 (3): 238–251.
Bi J, Ma H, Zhang D, et al. Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection?. Eur Respir J 2020;56:2002672.
ESMO. ESMO-EHA clinical practice guidelines for the management of malignant lymphoma–recommendations for the second phase of the COVID-19 pandemic: Aggressive lymphoma (Diffuse large B-cell lymphoma, Mantle cell and T-cell lymphomas) [Internet]. [cited 2020. Dec 30]. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphoma-in-the-second-phase-of-the-covid-19-pandemic-esmo-eha.
Li J, Zhang L, Liu B, et al. Case report: viral shedding for 60 days in a woman with COVID-19. Am J Trop Med Hyg. 2020; 102 (6): 1210–1213.
Bose G, Galetta K. Reactivation of SARS-CoV-2 after rituximab in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021; 52: 102922.
Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011; 77 (3): 221–240.
Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-Treatment interval is an important clinical factor in newly diagnosed diffuse large B-Cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018; 36 (16): 1603–1610.
